Thermo Scientific issues software update after confirming bug in its bioequivalence data platform

By Dan Stanton contact

- Last updated on GMT

Thermo Scientific find bug in its software system
Thermo Scientific find bug in its software system

Related tags: Thermo fisher scientific, Thermo electron

Thermo Fisher Scientific has issued a letter to users of its Kinetica technology software confirming discrepancies in its bioequivalence data.

A paper published in the AAPS journal in September found discrepancies with PK/PD data analysis software packages, with the authors pointing at Thermo Fisher Scientific’s platform Kinetica as potentially having an error which could mean some drugs were inaccurately approved by regulatory bodies.

At the time the company told in-Pharmatechnologist.com​ it was conducting a review of the system and in a letter sent to users of Kinetica– and provided to this publication by Helmut Schütz, one of the authors of the AAPS paper - the firm has said the internal investigation has confirmed the issues thrown up in the journal.

“The [AAPS] article discussed the validation of software used to assess bioequivalence and reported that results from Kinetica software differed from other software when unbalanced datasets were used,”​ the letter dated October 29 states.

“Kinetica software does employ an algorithm for a balanced design in both the cases of balanced and unbalanced studies. Therefore, any results from unbalanced studies would be inaccurate.”

While individual cases may differ, the firm believes that in most cases this error would result in only a small difference in the overall results, and the company is “currently implementing a software update and will be performing rigorous testing to ensure that this issue is resolved.”

Thermo Scientific has also sent a letter to the European Medicines Agency (EMA), Sophie Labbé a spokesperson from the regulator confirmed, telling us the issues raised by the paper were discussed by the CHMP’s Pharmacokinetic Working Party at its meeting on 21-22 October.

“The letter and the company’s intention to update the software will be considered by the Agency,”​ she told us, adding “the findings do not warrant immediate regulatory actions.”

Related news

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars